500 Global Taps UN SDG Architect, Dr. Alaa Murabit, to Launch Firm’s New Offerings in Sustainable Growth
21.7.2025 10:00:00 CEST | Business Wire | Press Release
500 Global, one of the world’s most active venture capital firms1, today announced the appointment of Dr. Alaa Murabit as Managing Partner of Sustainable Growth. She will oversee the firm’s Sustainable Growth practice created to accelerate economic resilience by mobilizing capital and capabilities across climate, health and human development in frontier and emerging markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250721464209/en/
500 Global’s Sustainable Growth practice aims to create financing strategies, educational programs, advisory platforms, and catalytic initiatives that bring together public, private, and philanthropic capital to deliver sustainable economic results.
A globally recognized expert in health, climate, sustainable development, and inclusive security, Dr. Alaa Murabit has shaped policies and financing that have impacted 193+ countries, played a pivotal role in the creation of the United Nations Sustainable Development Goals and mobilized over $25 billion in financing for global health, sustainability, and security. Dr. Alaa Murabit led Phase Minus 1, was CEO of IMPACT2030, and, most recently, created two innovative financing platforms and directed a $300M/year global portfolio at the Gates Foundation, leading maternal and child health, climate and health security, and innovation.
“Economic development has always been an impact of the investments 500 Global has made, and we’re delighted that Dr. Alaa Murabit has joined us to multiply that impact. Her appointment reinforces the growing global consensus that venture capital, when aligned with national priorities and de-risked through blended finance and public-private partnerships, can serve as a catalytic engine for inclusive growth and long-term development impact.“ – Courtney Powell, COO & Managing Partner, 500 Global
In an era marked by climate shocks, geopolitical volatility, and rising inequality, the need for resilient, inclusive economic systems has never been greater. Dr. Alaa Murabit’s appointment signals a strategic shift in emerging markets: from fragmented, short-cycle investments to long-term value creation through blended finance, public-private alignment, and co-created national innovation infrastructure. Her leadership will expand 500 Global’s ability to work with sovereign funds, governments, development finance institutions, and philanthropies to scale inclusive economic growth by de-risking investment and innovation. She will be based in Abu Dhabi, United Arab Emirates.
500 Global has been committed to ecosystem development since 2010. Working closely with national allocators like Georgia’s Information and Technology Agency and Sanabil Investments (a wholly owned subsidiary of Saudi Arabia’s Public Investment Fund), the firm has embedded and developed its investment thesis by co-creating localized venture capital infrastructure to address local challenges and scale solutions globally.
In 2023, they launched the Rise Report, which highlighted 30 rise economies - the 30 largest, fast growing economies outside of the US and China - inclusive of Mexico, Egypt, Saudi Arabia, India, South Korea and more where 500 has had an ongoing presence. This report examined potential venture funding gaps; inviting allocators and policymakers to join forces toward the goal of accelerating global venture ecosystems that drive national development, economic growth and resilience.
With Dr. Alaa Murabit’s appointment, 500 Global is doubling down, replacing fragmented development efforts with scalable public-private finance strategies, and building the enabling environment for sustainable economic transformation.
“Too often, global capital reaches communities late — or not at all. We need to redesign financing systems that prioritize local innovation, share risk more equitably, and align investment with sustainable, inclusive outcomes. 500 Global is showing what’s possible when we reimagine how capital serves both people and planet. I’m excited to lead and advance that vision globally.” – Dr. Alaa Murabit, Managing Partner, Sustainable Growth, 500 Global
About 500 Global
500 Global is a multi-stage venture capital firm with $2.1B in assets under management2 that invests in founders building fast-growing technology companies. We focus on markets where technology, innovation, and capital can unlock long-term value and drive economic growth and development. We work closely with key stakeholders and advise governments on how best to support entrepreneurial ecosystems and economic development in emerging markets. 500 Global has backed over 5,000 founders representing more than 3,000 companies operating in 80+ countries. We have invested in more than 35+ companies valued at over $1 billion and 150+ companies valued at over $100 million (including private, public, and exited companies)3.
THE CONTENT IN THIS PRESS RELEASE IS PROVIDED FOR GENERAL INFORMATIONAL OR EDUCATIONAL PURPOSES ONLY. 500 GLOBAL MAKES NO REPRESENTATIONS AS TO THE ACCURACY OR INFORMATION CONTAINED HEREIN AND WHILE 500 GLOBAL HAS TAKEN REASONABLE STEPS TO ENSURE THAT THE INFORMATION CONTAINED HEREIN IS ACCURATE AND UP-TO-DATE, NO LIABILITY CAN BE ACCEPTED FOR ANY ERROR OR OMISSIONS. UNLESS OTHERWISE STATED IN THIS PRESS RELEASE, ANY PREDICTIONS, FORECASTS, CONCLUSIONS, VIEWS OR OPINIONS EXPRESSED REPRESENT THE CURRENT VIEW AND THINKING OF 500 GLOBAL WITH REGARD TO THE SUBJECT MATTER THEREIN BASED ON INTERNAL DATA AGGREGATED ACROSS ALL 500 GLOBAL FUNDS AS OF MARCH 31, 2025 AND/OR ANALYSIS WHICH HAS NOT BEEN INDEPENDENTLY VERIFIED, AND WHICH IS SUBJECT TO CHANGE AT ANY TIME.
UNDER NO CIRCUMSTANCES SHOULD ANY OF THE CONTENT IN THIS PRESS RELEASE BE CONSTRUED AS LEGAL, TAX OR INVESTMENT ADVICE FROM 500 GLOBAL OR ANY OF ITS AFFILIATES. 500 GLOBAL DOES NOT GUARANTEE ANY FUTURE RESULTS FOR ANY DECISIONS MADE BASED IN WHOLE OR IN PART ON THE CONTENT OR INFORMATION CONTAINED HEREIN. ALL READERS OF THIS PRESS RELEASE SHOULD CONSULT WITH THEIR OWN COUNSEL, ACCOUNTANT OR OTHER PROFESSIONAL ADVISORS BEFORE TAKING ANY ACTION IN CONNECTION WITH THIS PRESS RELEASE.
UNDER NO CIRCUMSTANCES SHOULD ANY INFORMATION OR CONTENT IN THIS PRESS RELEASE, BE CONSIDERED AS AN OFFER TO SELL OR SOLICITATION OF INTEREST TO PURCHASE ANY SECURITIES ADVISED BY 500 GLOBAL OR ANY OF ITS AFFILIATES OR REPRESENTATIVES. FURTHER, NO CONTENT OR INFORMATION CONTAINED IN THIS PRESS RELEASE IS OR IS INTENDED AS AN OFFER TO PROVIDE ANY INVESTMENT ADVISORY SERVICE OR FINANCIAL ADVICE BY 500 GLOBAL. UNDER NO CIRCUMSTANCES SHOULD ANYTHING HEREIN BE CONSTRUED AS FUND MARKETING MATERIALS BY PROSPECTIVE INVESTORS CONSIDERING AN INVESTMENT INTO ANY 500 GLOBAL INVESTMENT FUND. UNDER NO CIRCUMSTANCES SHOULD ANY CONTENT BE INTERPRETED AS TESTIMONIALS OR ENDORSEMENT OF THE INVESTMENT PERFORMANCE OF ANY 500 GLOBAL FUND BY A PROSPECTIVE INVESTOR CONSIDERING AN INVESTMENT INTO ANY 500 GLOBAL FUND.
| ____________________ | |
1 | Based on PitchBook’s 2024 Global League Tables. |
2 | ASSETS UNDER MANAGEMENT (AUM) CALCULATIONS ARE BASED ON INTERNAL ESTIMATES AS OF MARCH 31, 2025. |
3 | AS OF DECEMBER 31, 2024. INCLUDES PRIVATE, PUBLIC AND EXITED COMPANIES. FOR EXITED POSITIONS, VALUATION DATE IS DATE OF EXIT. THESE FIGURES ARE ESTIMATES, AGGREGATED ACROSS ALL PORTFOLIO COMPANIES HELD ACROSS ALL FUNDS ADVISED BY 500 GLOBAL AND ITS AFFILIATES, AND ARE BASED ON INTERNAL DATA AND PORTFOLIO INFORMATION SUPPLIED BY EXTERNAL SOURCES WHICH HAVE NOT BEEN VERIFIED, AND MAY NOT BE ACCURATE OR UPDATED. THESE VALUATIONS ARE ESTIMATED IN ACCORDANCE WITH 500 GLOBAL’S VALUATION POLICY. SEE 500.CO/COMPANIES FOR A FULL LIST OF PORTFOLIO COMPANIES. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250721464209/en/
Contacts
Media Contacts
Media Relations at 500 Global
press@500.co
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom